SK BIOSCIENCE LOOKING AT AN IPO MONEYSPINNER WITH ASTRAZENECA COVID-19 VACCINE DEAL

• Ever since a deal was reached in July for SK Bioscience to manufacture AstraZeneca's COVID-19 vaccine, the SK subsidiary has already succeeded in producing the vaccine at its Andong L HOUSE vaccine center.
• While some vials of the vaccine produced have already been exported,...

IPO STOCKS IN THAILAND AND SOUTH KOREA SURGE

HIGHLIGHTS

• Investors are snapping up shares in drugmaker called SK Biopharm and glove producer Sri Trang.
• The shares of both companies are have risen above their IPO prices.

Investors in Thailand and South Korea snapped up shares in ...

SK HOLDINGS SUBSIDIARY COMPANIES ARE GAINING WELL IN STOCK MARKET

Highlights –

• SK Holdings saw share price gain by nearly 3 percent.
• The gains happened so because of its biotech subsidiary company.
•  SK Pharmteco will provide Virginia-based Phlow with active pharmaceutical ingredients.

$43M raised by Clover Biopharmaceuticals in Series B Funding

Based in China, the global clinical-stage bio-tech company Clover Biopharmaceuticalsis focusing on innovative biologic therapies, sealed a US$ 43m (RMB 304m) Series B financing.

Lead by Delos Capital and Lapam Capital, along with some help by from Betta Capital, Sichuan Health Care Indu...

Phase 1 SCB-313 for Malignant Pleural Effusion Treatment tested by Clover Biopharmaceuticals in Australia

According to an announcement by an international biotechnology company in China, Clover Biopharmaceuticals, thriving to develop new biological therapies, the first-ever cancer patient suffering from malignant pleural effusions was admitted in Australia in a fully human TRAIL-Trimer fusion protein...

Australia: Clover Biopharmaceuticals tests Phase 1 study of SCB-313 for Malignant Pleural Effusion

CHENGDU, China ( November 21, 2019 ) Clover Biopharmaceuticals, an international clinical-stage biotechnology company based on the development of novel and revelatory biological therapies, announced today that the very first patient was administered in Australia for the treatment of cancer patien...

First Patient Dosed in Phase I Study of SCB-313 for MPE by Clover Biopharmaceuticals

International clinical-stage biotechnology engaged in generating new and transformative biologic treatments, Clover Biopharmaceuticals publicized today how they had dosed their first patient in a Phase I trial of SCB-313 in Australia for treating cancer patients having malignant pleural effusions...

AstraZeneca diabetes drug approved for treating heart failure risk

AstraZeneca's diabetes drug Farxiga has been approved to be used within USA as a treatment to cut back the probabilities of medical aid for a heart condition in adults with type-2 diabetes and alternative vessel risks, British drug maker same on Mon.

The approval by the U.S. Food an...